幹細胞論壇

該文獻表示，使用造血幹細胞移植的發生率隨著年齡增加，特別在40歲以後。40歲以上的發生率男性高於女性。在目前的適應症內，一生中使用自體或異體造血幹細胞移植的機率比先前報導高很多，若造血幹細胞之可行性及適用性增加，未來使用機率會更高。 

內文頁5

70歲以前，使用自體造血幹細胞移植機率約為1/400，異體造血幹細胞移植機率為1/400，自體和異體造血幹細胞移植機率為1/200。

**本篇研究針對年紀、性別和種族不同來評估美國近年來造血幹細胞的使用機率。根據國際血液及骨髓移植研究中心、美國癌症登記及美國人口普查局，計算使用機率。

LIFETIME PROBABILITIES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE US

Abstract

Health care policies regarding hematopoietic stem cell transplantation (HCT) must address the need for the procedure as well as the availability of stem cell sources: bone marrow, peripheral blood, or umbilical cord blood (UCB). However, data with respect to the lifetime probability of undergoing HCT are lacking.

This study was undertaken to estimate the latter probability in the United States (US), depending on age, gender and race. We used data from the Center for International Blood and Marrow Transplant Research, the US Surveillance, Epidemiology and End Results Program and the US Census Bureau and calculated probabilities as cumulative incidences. Several scenarios were considered: assuming current indications for autologous and allogeneic HCT, assuming universal donor availability, and assuming broadening of HCT use in hematologic malignancies.

Incidences of diseases treated with HCT and of HCTs performed increase with age, rising strongly after age 40. Among individuals older than 40, incidences are higher for men than for women. The lifetime probabilities of undergoing HCT range from 0.23% to 0.98% under the various scenarios. We conclude that, given current indications, the lifetime probability of undergoing autologous or allogeneic HCT is much higher than previously reported by others and could rise even higher with increases in donor availability and HCT applicability.

Page 5

Under Scenario 1, CIBMTR data indicate that the lifetime probability of undergoing an autologous HCT in the US is about 1:400 if the indications for autologous HCT do not change much during the next 70 years. …. Under Scenarios 2 and 3, the lifetime probabilities are 1:400 and 1:200, respectively, for undergoing allogeneic HCT or either autologous or allogeneic HCT.

Biol Blood Marrow Transplant. 2008 March ; 14(3): 316–322.

http://parentsguidecordblood.org/en/cord-blood-infographic